Non-alcoholic steatohepatitis-related cirrhosis in a patient with APOB L343V familial hypobetalipoproteinaemia

Clinica Chimica Acta

Volumn 421, Issue , 2013, Pages 121-125

  Heeks, Liesl V ^a   Hooper, Amanda J ^a,b,c   Adams, Leon A ^b,d   Robbins, Peter ^e   Barrett, P Hugh R ^b,c   van Bockxmeer, Frank M ^a,c   Burnett, John R ^a,b,c  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Apolipoprotein B; Cirrhosis; Familial hypobetalipoproteinaemia; LDL cholesterol; Non alcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HYALURONIC ACID; INSULIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; APOB GENE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CASE REPORT; DISEASE COURSE; ECHOGRAPHY; ELASTOGRAPHY; FAMILIAL HYPOBETALIPOPROTEINEMIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MALE; MEDICAL HISTORY; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE;

AMINO ACID SUBSTITUTION; APOLIPOPROTEINS B; FATTY LIVER; FEMALE; HETEROZYGOTE; HUMANS; HYPOBETALIPOPROTEINEMIA, FAMILIAL, APOLIPOPROTEIN B; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; OBESITY;

EID: 84875800589     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.03.004     Document Type: Article

References (28)

1. Hooper A.J., van Bockxmeer F.M., Burnett J.R. Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism. Crit Rev Clin Lab Sci 2005, 42:515-545.
2. Tarugi P., Averna M. Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum. Adv Clin Chem 2011, 54:81-107.
3. Whitfield A.J., Barrett P.H.R., van Bockxmeer F.M., Burnett J.R. Lipid disorders and mutations in the APOB gene. Clin Chem 2004, 50:1725-1732.
4. Glueck C.J., Gartside P., Fallat R.W., Sielski J., Steiner P.M. Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med 1976, 88:941-957.
5. Burnett J.R., Shan J., Miskie B.A., et al. A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia. J Biol Chem 2003, 278:13442-13452.
6. Burnett J.R., Zhong S., Jiang Z.G., et al. Missense mutations in APOB within the βα1 domain of human APOB-100 result in impaired secretion of apoB and apoB-containing lipoproteins in familial hypobetalipoproteinemia. J Biol Chem 2007, 282:24270-24283.
7. Zhong S., Magnolo A.L., Sundaram M., et al. Nonsynonymous mutations within APOB in human familial hypobetalipoproteinemia - evidence for feedback inhibition of lipogenesis and post-endoplasmic reticulum degradation of apolipoprotein B. J Biol Chem 2010, 285:6453-6464.
8. Hooper A.J., Marais A.D., Tanyanyiwa D.M., Burnett J.R. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007, 193:445-448.
9. Zhao Z., Tuakli-Wosornu Y., Lagace T.A., et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006, 79:514-523.
10. Schonfeld G., Patterson B.W., Yablonskiy D.A., et al. Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J Lipid Res 2003, 44:470-478.
11. Tanoli T., Yue P., Yablonskiy D., Schonfeld G. Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res 2004, 45:941-947.
12. Whitfield A.J., Barrett P.H.R., Robertson K., Havlat M.F., van Bockxmeer F.M., Burnett J.R. Liver dysfunction and steatosis in familial hypobetalipoproteinemia. Clin Chem 2005, 51:266-269.
13. Hooper A.J., Adams L.A., Burnett J.R. Genetic determinants of hepatic steatosis in man. J Lipid Res 2011, 52:593-617.
14. Adams L.A., George J., Bugianesi E., et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2011, 26:1536-1543.
15. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
16. Smith B.W., Adams L.A. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci 2011, 48:97-113.
17. Sankatsing R.R., Fouchier S.W., de Haan S., et al. Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 2005, 25:1979-1984.
18. Ballestri S., Lonardo A., Losi L., Pellegrini E., Bertolotti M., Loria P. Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?. Intern Emerg Med 2009, 4:71-73.
19. Di Leo E., Magnolo L., Bertolotti M., et al. Variable phenotypic expression of homozygous familial hypobetalipoproteinaemia due to novel APOB gene mutations. Clin Genet 2008, 74:267-273.
20. Harada N., Soejima Y., Taketomi A., et al. Recurrent familial hypobetalipoproteinemia-induced nonalcoholic fatty liver disease after living donor liver transplantation. Liver Transpl 2009, 15:806-809.
21. Lam M.C., Singham J., Hegele R.A., et al. Familial hypobetalipoproteinemia-induced nonalcoholic steatohepatitis. Case Rep Gastroenterol 2012, 6:429-437.
22. Lonardo A., Bagni A., Tarugi P., Loria P. The wide spectrum of steatohepatitis: a report of four cases and a review of the literature. Eur J Gastroenterol Hepatol 2004, 16:1043-1050.
23. Lonardo A., Tarugi P., Ballarini G., Bagni A. Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. Dig Dis Sci 1998, 43:2489-2492.
24. Tarugi P., Lonardo A., Ballarini G., et al. A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5). J Hepatol 2000, 33:361-370.
25. Lin X., Schonfeld G., Yue P., Chen Z. Hepatic fatty acid synthesis is suppressed in mice with fatty livers due to targeted apolipoprotein B38.9 mutation. Arterioscler Thromb Vasc Biol 2002, 22:476-482.
26. Lin X., Yue P., Xie Y., et al. Reduced intestinal fat absorptive capacity but enhanced susceptibility to diet-induced fatty liver in mice heterozygous for ApoB38.9 truncation. Am J Physiol Gastrointest Liver Physiol 2005, 289:146-152.
27. Machado M., Marques-Vidal P., Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006, 45:600-606.
28. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.